BioSpace News Archive

Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors, announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference.

REGN-EB3 is a novel anti-viral antibody cocktail developed using the same rapid response technologies as REGN-COV2, Regeneron’s investigational COVID-19 antibody cocktail

Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at BTIG’s Virtual Biotechnology Conference on Monday August 10, 2020 at 11 a.m. EDT. A live webcast of this presentation will be available under “ Events, Webcasts and Presentations ” in the investors section of the IMV website and a rep

Cutera, Inc., a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced that it will report financial results for the second quarter 2020 after the market close on Thursday, August 6, 2020.

Targeting axonal degeneration and neuroinflammation, early hallmarks of several acute and chronic neurological diseases

Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its second quarter 2020 financial results on Wednesday, August 5, 2020 and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company’s financial results and provide

Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) and off-the-shelf NK (oNK) technology today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. The company will deliver a corporate update to potential investors and strategic partners among other various relevant audiences. The corpor

Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness DURHAM, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that it has acquired exclusive rights to a gene therapy targeting GUCY2D -

Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 2020